NCT07053345View on ClinicalTrials.gov

A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression

PHASE4RecruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

June 25, 2027

Study Completion Date

June 25, 2027

Conditions
Depressive Disorder, Treatment-Resistant
Interventions
DRUG

Esketamine 56 mg

Participants will self-administer 56 mg of esketamine as intranasal spray into each nostril.

DRUG

Esketamine 84 mg

Participants will self-administer 84 mg of esketamine as intranasal spray into each nostril.

Trial Locations (6)

10414

RECRUITING

Cha Ilsan Medical Center, Goyang Si Gyeonggi Do

570 711

RECRUITING

Wonkwang University Hospital, Iksan

02447

RECRUITING

Kyung Hee University Medical Center, Seoul

03181

RECRUITING

Kangbuk Samsung Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Janssen Korea, Ltd., Korea

INDUSTRY